Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
Immune Design (IMDZ) Misses Q4 EPS by 6c
March 10, 2016 4:13 PM ESTImmune Design (NASDAQ: IMDZ) reported Q4 EPS of ($0.60), $0.06 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.06 million.
For earnings history and earnings-related data on Immune Design (IMDZ) click here.
... More


